• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diabetol Metab Syndr . Association between inpatient glycemic variability and COVID-19 mortality: a prospective study

tetano

Editor, Senior Moderator
Diabetol Metab Syndr


. 2023 Sep 11;15(1):185.
doi: 10.1186/s13098-023-01157-z. Association between inpatient glycemic variability and COVID-19 mortality: a prospective study

Salma Ali El Chab Parolin[SUP] 1 [/SUP], Rebecca Benicio Stocco[SUP] 2 [/SUP], Julia do Carmo Kneipp Lopes[SUP] 2 [/SUP], Marcos Roberto Curcio Pereira[SUP] 2 [/SUP], Milena Massae Yamashita[SUP] 2 [/SUP], Maria Eduarda Domareski Goulart[SUP] 2 [/SUP], Henrique Demeneck[SUP] 2 [/SUP], Marcia Olandoski[SUP] 2 [/SUP], Larissa Hermann de Souza Nunes[SUP] 2 [/SUP], Victor Keniche Morisawa[SUP] 2 [/SUP], Luiz Augusto Fanhani Cracco[SUP] 2 [/SUP], Isabela Busto Silva[SUP] 2 [/SUP], Jarbas Silva Motta Júnior[SUP] 2 [/SUP], Daniela Veit Barreto[SUP] 2 [/SUP], Gustavo Lenci Marques[SUP] 2 [/SUP], Thyago Proença de Moraes[SUP] 2 [/SUP], Cristina Pellegrino Baena[SUP] 2 [/SUP]



Affiliations
Abstract

Background: This study aimed to determine the association between glycemic variability (GV) and mortality in hospitalized patients with coronavirus disease 2019 (COVID-19).
Methods: We prospectively analyzed data from inpatients (> 18 years old) with RT-PCR confirmed COVID-19 admitted between March 2020 and July 2021. All patients were hospitalized for more than 48 h and had at least six point-of-care capillary glucose tests obtained three times daily in the pre-prandial period during hospitalization. GV was measured using the glucose standard deviation (SD) and coefficient of variation (CV). ROC curve was adjusted to determine the SD and CV cutoff values associated with mortality (44.7 mg/dL and 27.5%, respectively); values above these were considered indicative of high GV. Logistic regression models were fitted to explore the association between GV and mortality in patients with and without diabetes.
Results: A total of 628 patients were stratified into SD < 44.7 mg/dL (n = 357) versus ≥ 44.7 mg/dL (n = 271) and CV < 27.5% (n = 318) versus ≥ 27.5% (n = 310) groups. After controlling for age, sex, presence of diabetes mellitus (DM) and cardiovascular disease, we found a significant association between high GV and mortality (odds ratio 2.99 [1.88-4.77] for SD and 2.43 [1.54-3.85] for CV; p values < 0.001). The mortality rate was higher with SD ≥ 44.7 mg/dL and CV ≥ 27.5% compared to that with SD < 44.7 mg/dL and CV < 27.5%, regardless of DM (p < 0.001 for all).
Conclusion: High glycemic variability was independently associated with mortality in patients with and without DM, who were hospitalized with COVID-19.

Keywords: COVID-19; Glycemic variability; Mortality, inpatient.

 
Back
Top Bottom